A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
about
Lupus Nephritis in Asia: Clinical Features and ManagementCurrent and emerging treatment options in the management of lupusB cells with regulatory properties in transplantation toleranceKey issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implicationsUpdate on mesenchymal stem cell-based therapy in lupus and sclerodermaBelimumab in systemic lupus erythematosusCytokines and MicroRNAs as Candidate Biomarkers for Systemic Lupus ErythematosusUse of biologics in SLE: a review of the evidence from a clinical perspectiveB-cell survival factors in autoimmune rheumatic disordersBelimumab in systemic lupus erythematosus: a perspective reviewMeasuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical researchCellular targeting in autoimmunityThe rationale for BAFF inhibition in systemic lupus erythematosusNational Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group ReportProfile of atacicept and its potential in the treatment of systemic lupus erythematosusEffect of TACI signaling on humoral immunity and autoimmune diseasesUnmet medical needs in systemic lupus erythematosusDrugs derived from phage display: from candidate identification to clinical practiceApproaches for estimating minimal clinically important differences in systemic lupus erythematosusTargeting dendritic cell function during systemic autoimmunity to restore tolerancePathogenesis of renal disease in systemic lupus erythematosus--the role of autoantibodies and lymphocytes subset abnormalitiesFrom BILAG to BILAG-based combined lupus assessment-30 years onWhat is new in the management of rapidly progressive glomerulonephritis?Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre studyBelimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysisThe pathogenesis of systemic lupus erythematosus—an updatePatient-reported outcomes in lupus clinical trials with biologics.First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study.Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.The pathogenesis, diagnosis and treatment of lupus nephritis.Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).Failure of a systemic lupus erythematosus response index developed from clinical trial data: lessons examined and learned.Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease.Pathways leading to an immunological disease: systemic lupus erythematosus.Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada StudyEfficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.Recent advances in the understanding of renal inflammation and fibrosis in lupus nephritis.Type I interferon in the pathogenesis of lupus.
P2860
Q26740487-F0EC738A-0FB0-4D07-B8CC-E6C1C1867239Q26741266-8A8CB7EF-BB73-47C1-8236-C068E96B4FD8Q26771404-235334BB-3F19-4426-B88F-C58F3F39E872Q26775756-857A0EDA-9571-461F-9F4A-64AE6715C402Q26777402-088355F8-9D11-4BD4-9AAF-CDB870DFC7C0Q26778277-77B8CFA1-BAE1-44DB-8728-993A0C1E7DBBQ26782454-A49FC706-FD84-417D-A393-6DA793F35CA0Q26783652-EEEBDFFB-41BD-4292-9467-D1F47C8E0CADQ26796484-C694F4DF-6213-4CF2-BAAE-3F2C87BCBB19Q26796486-BB353BA4-7790-4376-A3B6-565B5CA7833DQ26799223-FB3AE120-6BE7-4FE9-A798-E46A7E78DC17Q26824580-5A5318B7-F0F2-4B54-A740-89D3F9D32228Q26827373-781BE423-8A7A-4B21-A5BA-C162895C26BFQ26827651-EF539FD6-1F05-44B1-9266-A28C7826020EQ26849719-78366502-BC8F-434B-89C1-A1F3BBEA90FEQ26995571-0A2E4E0F-16C9-48EB-BD38-64C964EB6762Q27005906-10D34989-9199-4600-B455-43C1AAFF41A9Q27007101-E431B3CA-6258-44AA-A510-780A86DEB4A1Q27021623-2397A27A-B868-46B1-8A45-62C0E5664728Q27687098-1D1DBCAD-2459-4DBF-8B67-6F5C40A450E1Q28080571-187CBC40-C786-4D26-9668-7B941369A039Q28081809-3E42EEA0-EB74-402A-BFDB-FF9233151DB9Q28259540-A7A2C6E3-E686-4D36-9C66-17F567E948ADQ28660706-1155CDE2-8400-45F6-A057-979D9EEF9565Q28676968-635A1430-D4EC-4BEC-9AA5-C609DC10E404Q29394347-4988E7AA-B1BA-4C8E-8581-FD968077FCB9Q30391564-131A3AD3-2ADD-445F-B025-8776857FB19EQ30490276-EBECCDE3-35A2-46B9-A124-EA6320ADA4ECQ30580226-7CADCC39-CCAF-4E0D-84F0-76738D0B79E2Q30596968-80ADB8B9-145B-4593-B65A-EE2BA70A94ECQ30645037-46F831D6-E2D3-4641-A821-0C932DAAF68EQ30832522-C4FCEA32-6BB4-43F3-AB39-BE2407C695AEQ31160251-EF6066F4-217A-4B81-A97A-8C48415EB0D9Q33431030-21E57FDB-872A-4541-B3D8-16D828EC386DQ33620555-22ED5290-C9C7-4F9B-A880-45212958DE15Q33695128-5DEFA2E6-6BF5-48C6-993F-39563A93E56DQ33698040-249BCABF-CA5F-41A0-B353-18AA8BE2CE9AQ33731705-DC2B7A78-6DE4-47B7-A68A-9BE509D2DF87Q33806541-D0541A36-7D13-4074-8540-69E09C8689A0Q33852174-D2559565-55F1-4055-8348-1C8ABC636F33
P2860
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A phase III, randomized, place ...... h systemic lupus erythematosus
@ast
A phase III, randomized, place ...... h systemic lupus erythematosus
@en
A phase III, randomized, place ...... h systemic lupus erythematosus
@nl
type
label
A phase III, randomized, place ...... h systemic lupus erythematosus
@ast
A phase III, randomized, place ...... h systemic lupus erythematosus
@en
A phase III, randomized, place ...... h systemic lupus erythematosus
@nl
prefLabel
A phase III, randomized, place ...... h systemic lupus erythematosus
@ast
A phase III, randomized, place ...... h systemic lupus erythematosus
@en
A phase III, randomized, place ...... h systemic lupus erythematosus
@nl
P2093
P2860
P50
P921
P3181
P356
P1476
A phase III, randomized, place ...... h systemic lupus erythematosus
@en
P2093
Andreas Schwarting
Daniel J Wallace
Ellen M Ginzler
Joan T Merrill
Jorge Sanchez-Guerrero
Omid Zamani
Richard Furie
W Winn Chatham
William Freimuth
William Stohl
P2860
P304
P3181
P356
10.1002/ART.30613
P407
P577
2011-12-01T00:00:00Z